NCT00645853View on ClinicalTrials.gov

Long-term Safety in Atrial Fibrillation Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

523

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Persistent or Permanent Nonvalvular Atrial Fibrillation

Interventions

DRUG

AZD0837

Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od

DRUG

VKA INR 2-3

Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5